Johan van Hylckama Vlieg
Gründer bei Freya Biosciences ApS
Ursprung des Netzwerks ersten Grades von Johan van Hylckama Vlieg
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 | |
Freya Biosciences ApS
 Freya Biosciences ApS Miscellaneous Commercial ServicesCommercial Services Freya Biosciences ApS is a clinical-stage biotech company based in Copenhagen, Denmark, that is dedicated to advancing women's reproductive health. The Danish company focuses on reproductive microbial immunotherapy interventions to improve fertility outcomes and empower women with innovative solutions. Freya Biosciences aims to address immune drivers underlying a range of reproductive health conditions to create a future where everyone is empowered with optimal reproductive health. The company was founded by Johan van Hylckama Vlieg, Colleen Acosta, Randi Rich, and Ulrich Binné, and Colleen Acosta has been the CEO since incorporation.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Johan van Hylckama Vlieg
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Public Communications Contact Corporate Officer/Principal | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Investor Relations Contact Director of Finance/CFO Director of Finance/CFO | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| MODERNA, INC. | Biotechnology | Director/Board Member Founder Human Resources Officer | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Chief Executive Officer Private Equity Investor | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO General Counsel Corporate Officer/Principal | |
| THERMO FISHER SCIENTIFIC | Medical Specialties | Director of Finance/CFO Public Communications Contact Director of Finance/CFO | |
| Massachusetts Institute of Technology | College/University | Director/Board Member Doctorate Degree Doctorate Degree | |
Indigo Ag, Inc.
 Indigo Ag, Inc. BiotechnologyHealth Technology Indigo Ag, Inc. provides microbial solutions. The company was founded by Noubar Afeyan, David A. Berry, and Geoffrey von Maltzahn in 2013 and is headquartered in Charlestown, MA. | Biotechnology | Founder Chief Tech/Sci/R&D Officer Founder | |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Biotechnology | Founder Founder | |
| AXCA HEALPAR | Biotechnology | Founder Founder | |
| Stanford University | College/University | Doctorate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder | |
| SERES THERAPEUTICS, INC. | Biotechnology | Founder Founder | |
Inzen Therapeutics, Inc.
 Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Biotechnology | Director/Board Member Director/Board Member | |
| SANA BIOTECHNOLOGY, INC. | Biotechnology | Founder Director/Board Member | |
Cobalt Biomedicine, Inc.
 Cobalt Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Cobalt Biomedicine, Inc. engages in the development of therapeutic based drugs. The company was founded in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
| Princeton University | College/University | Corporate Officer/Principal Undergraduate Degree | |
| RUBIUS THERAPEUTICS | Biotechnology | Founder Director/Board Member | |
| Boston College | College/University | Undergraduate Degree Undergraduate Degree | |
Regulatory Affairs Professionals Society
 Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| HAEMONETICS CORPORATION | Medical Specialties | Director of Finance/CFO Corporate Officer/Principal | |
| University of Massachusetts | College/University | Undergraduate Degree Masters Business Admin | |
| PEPSICO, INC. | Food: Specialty/Candy | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| X4 PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Comptroller/Controller/Auditor | |
| DIANTHUS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| REZOLUTE, INC. | Pharmaceuticals: Major | General Counsel | |
| VERASTEM, INC. | Biotechnology | Director/Board Member | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor | |
| University of Notre Dame | College/University | Undergraduate Degree | |
| ZELTIQ AESTHETICS INC | Medical Specialties | Director of Finance/CFO | |
| SIENNA BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
| King's College London | College/University | Undergraduate Degree | |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Chairman | |
| ARAVIVE, INC. | Biotechnology | Director of Finance/CFO | |
| CANDEL THERAPEUTICS, INC. | Biotechnology | General Counsel |
Statistik
International
| Vereinigte Staaten | 48 |
| Vereinigtes Königreich | 3 |
Sektoral
| Health Technology | 35 |
| Consumer Services | 9 |
| Finance | 4 |
| Commercial Services | 4 |
| Consumer Non-Durables | 2 |
Operativ
| Director/Board Member | 175 |
| Founder | 70 |
| Corporate Officer/Principal | 63 |
| Independent Dir/Board Member | 54 |
| Chairman | 42 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Noubar Afeyan | 76 |
| John Sculley | 39 |
| Michael Bonney | 32 |
| Theo Melas-Kyriazi | 26 |
| Alison Lawton | 24 |
| Bonnie Bassler | 20 |
| R. Grady Burnett | 16 |
| Susan Stewart | 15 |
| Geoffrey von Maltzahn | 15 |
| Anne Prener | 14 |
| Daniel L. Menichella | 13 |
| Katharine Knobil | 12 |
| Joshua Brumm | 11 |
| William Duke | 11 |
| Jean K. Mixer | 10 |
- Börse
- Insiders
- Johan van Hylckama Vlieg
- Unternehmensverbindungen
